CHICAGO, Ill. (February 6, 2010) -- In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting ™, in Chicago, researchers will unveil findings that show that there is an increased risk of intrauterine fetal death (IUFD), commonly known as stillbirth, in women who have fibroids.
IUFD, or still birth, is rare and affects only six to seven out of every thousand births.
The study, conducted by researchers at Washington University in St. Louis, Mo., identified women who had fibroids detected during their routine second trimester ultrasound for anatomic survey at 16-22 weeks.
"Fibroids are very common," said Dr. Molly J. Stout, one of the study's authors. "We think they occur in 5% to 20% of all women, but most women are asymptomatic and don't even know they have them."
The study was a retrospective cohort study of 64,047 women. Data were extracted on maternal sociodemographics, medical history, and obstetric outcomes. Pregnancies with any fetal anomalies were excluded. Women with at least one fibroid detected at the time of fetal anatomic survey were compared to women without fibroids. The primary outcome was IUFD after 20 weeks gestation. Univariate and multiple logistic regression analyses were used to estimate the risk of IUFD in women with fibroids, and subgroup was conducted by presence or absence of fetal growth restriction (IUGR).
The study found that of 64,047 women, the incidence of fibroids was 3.2% (n=2,058). The incidence of IUFD was significantly higher in the fibroid group than in the no-fibroid group (1.6% v. 0.7%, aOR 1.8, 95%CI 1.3-2.7) even after adjusting for factors including black race, tobacco exposure, chronic hypertension, and pregestational diabetes. In subgroup analysis, the risk relationship between fibroids and IUFD only persisted within the IUGR subgroup.
"Our results showed that women with a combination of fibroids and fetal growth restriction were at two-and-a-half times the risk of having a stillbirth, though the absolute risk remained rare," said Dr. Alison G. Cahill, another of the study's authors. "This may lead to a future recommendation for serial growth scans to monitor fetal growth in women with fibroids."
For interviews or a copy of the abstract please contact Vicki Bendure, at Vicki@bendurepr.com or 202-374-9259.
The Society for Maternal-Fetal Medicine (est. 1977) is a non-profit membership group for obstetricians/gynecologists who have additional formal education and training in maternal-fetal medicine. The society is devoted to reducing high-risk pregnancy complications by providing continuing education to its 2,000 members on the latest pregnancy assessment and treatment methods. It also serves as an advocate for improving public policy, and expanding research funding and opportunities for maternal-fetal medicine. The group hosts an annual scientific meeting in which new ideas and research in the area of maternal-fetal medicine are unveiled and discussed. For more information, visit www.smfm.org.